AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: 19112278
Drug: Sodium bicarbonate
RxNorm normalized name: Sodium Bicarbonate
DrugBank: Sodium bicarbonate (DB01390)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Sodium bicarbonate infusion (4 mmol/kg)
Trial: 15517671
Drug: Periurethral injection
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Periurethral injection
Trial: 15517671
Drug: Transurethral injection
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Transurethral injection
Trial: 10514756
Drug: Musical therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Musical therapy
Trial: 10514756
Drug: Control group
RxNorm normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control group (no musical therapy)
Trial: 8056006
Drug: Heparin (100
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Heparin (100 U.kg‐1 intravenously bolus before thrombolytic treatment and additional intravenous heparin to raise partial thromboplastin time to 2-2.5 times normal)
Trial: 8056006
Drug: Heparin (Group
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Heparin (Group 1)
Trial: 8056006
Drug: Control (no
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control (no heparin, Group 2)
Trial: 25891021
Drug: Active tDCS
RxNorm normalized name: Activated Charcoal
DrugBank: Activated charcoal (DB09278)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Active tDCS (2 mA amplitude, 20 min daily for 5 days)
Trial: 11137262
Drug: Meningococcal group
RxNorm normalized name: meningococcal group B vaccine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Meningococcal group C/CRM (197) conjugate vaccine (3 doses at 2, 3, and 4 months)
Trial: 9543786
Drug: Hepatitis B
RxNorm normalized name: HEPATITIS B
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Hepatitis B vaccine (3 doses)
Trial: 11137262
Drug: Meningococcal group
RxNorm normalized name: meningococcal group B vaccine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Meningococcal group C/CRM (197) conjugate vaccine
Trial: 9087155
Drug: Nonsteroidal antiinflammatory
RxNorm normalized name: Arthriten Inflammatory Pain
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nonsteroidal antiinflammatory drugs (excluding those reported by the patient as responsible for previous reactions)
Trial: 9087155
Drug: Pyrazole derivatives
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pyrazole derivatives (most common nonsteroidal antiinflammatory drugs involved)
Trial: 17476567
Drug: Atrial natriuretic
RxNorm normalized name: Atrial natriuretic factor
DrugBank: Atrial natriuretic peptide (DB15591)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Atrial natriuretic peptide (ANP) infusion
Trial: 3300120
Drug: Metronidazole-gentamicin (M-G)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Metronidazole-gentamicin (M-G)
Trial: 26932256
Drug: Tissue tolerable
RxNorm normalized name: tissue respiratory factor
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tissue tolerable plasma (TTP) administered six times each 7 days
Trial: 26932256
Drug: Control (nystatin,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control (nystatin, chlorhexidine and placebo treatment)
Trial: 26573041
Drug: GnRH Agonist
RxNorm normalized name: GnRH
DrugBank: Gonadorelin (DB00644)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: GnRH Agonist Microdose Flareup (MF)
Trial: 26573041
Drug: GnRH Antagonist/Letrozole
FDA approved: no
EMA approved: no
PMDA approved: no
Description: GnRH Antagonist/Letrozole (AL)
Trial: 23840403
Drug: HAART and
RxNorm normalized name: cytarabine and daunorubicin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: HAART and TB treatment
Trial: 22024700
Drug: 500 mg
RxNorm normalized name: bran 500 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 500 mg oral levofloxacin
Trial: 2707923
Drug: 500 mg
RxNorm normalized name: bran 500 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 500 mg oral ciprofloxacin
Trial: 22024700
Drug: 250 mg
RxNorm normalized name: rutin 250 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 250 mg levofloxacin and 250 mg ciprofloxacin co-administered
Trial: 16493496
Drug: n-3 fatty
RxNorm normalized name: n-3 fatty acids
DrugBank: Omega-3 fatty acids (DB11133)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: n-3 fatty acids (4 g daily)
Trial: 16493496
Drug: corn oil
RxNorm normalized name: Corn Oil
FDA approved: no
EMA approved: no
PMDA approved: no
Description: corn oil (4 g daily)
Trial: 12867313
Drug: 1-l volume
RxNorm normalized name: VOLUME EXPANDERS
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1-l volume air pocket
Trial: 12867313
Drug: 2-l volume
RxNorm normalized name: Iron(2+) L-ascorbate
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 2-l volume air pocket
Trial: 10606835
Drug: Fleroxacin 400
RxNorm normalized name: fleroxacin 400 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fleroxacin 400 mg daily
Trial: 9107154
Drug: Meta-chlorophenylpiperazine (m-CPP)
RxNorm normalized name: m-phenylenediamine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Meta-chlorophenylpiperazine (m-CPP) infusion (0.08 mg/kg)
Trial: 3902199
Drug: Cisplatin (CACP)
RxNorm normalized name: Cisplatin
DrugBank: Cisplatin (DB00515)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Cisplatin (CACP) + 5-fluorouracil (5-FU) infusion (CACP 100 mg/m2 day 1 and 5-FU 1000 mg/m2 24-hour infusion days 1-4)
Trial: 3902199
Drug: Cisplatin (CACP)
RxNorm normalized name: Cisplatin
DrugBank: Cisplatin (DB00515)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Cisplatin (CACP) + 5-fluorouracil (5-FU) bolus (CACP 100 mg/m2 day 1 and 5-FU 600 mg/m2 day 1 and day 8)
Trial: 3902199
Drug: Cisplatin +
RxNorm normalized name: Cisplatin
DrugBank: Cisplatin (DB00515)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Cisplatin + 5-FU infusion
Trial: 21037028
Drug: Operative treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Operative treatment with accelerated functional rehabilitation
Trial: 21037028
Drug: Nonoperative treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nonoperative treatment with accelerated functional rehabilitation
Trial: 12505552
Drug: Psychological treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Psychological treatment for insomnia
Trial: 12505552
Drug: Control group
RxNorm normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control group (no psychological treatment)
Trial: 10211848
Drug: Zinc (25
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Zinc (25 mg)
Trial: 548558
Drug: PGF2 alpha
RxNorm normalized name: Prostaglandin PGF2 alpha
FDA approved: no
EMA approved: no
PMDA approved: no
Description: PGF2 alpha gel
Trial: 6575575
Drug: PGE2 tablets
RxNorm normalized name: PGE2
DrugBank: Dinoprostone (DB00917)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: PGE2 tablets
Trial: 21383110
Drug: Low MPH
RxNorm normalized name: low-density polyethylene
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Low MPH dose
Trial: 21383110
Drug: High MPH
RxNorm normalized name: high-density polyethylene
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High MPH dose
Trial: 19823178
Drug: Doxazosin 4
RxNorm normalized name: doxazosin 4 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Doxazosin 4 mg once daily for 6 weeks
Trial: 19823178
Drug: Doxazosin 4
RxNorm normalized name: doxazosin 4 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Doxazosin 4 mg once daily for 6 weeks in group I (ED)
Trial: 19823178
Drug: Doxazosin 4
RxNorm normalized name: doxazosin 4 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Doxazosin 4 mg once daily for 6 weeks in group II (no ED)
Trial: 11504824
Drug: Thalidomide, 200
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Thalidomide, 200 mg daily
Trial: 9011704
Drug: Warm bypass
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Warm bypass (37 degrees C, hematocrit 23%, pump flow 150 ml/kg per minute)
Trial: 9011704
Drug: Hypothermic low-flow
RxNorm normalized name: low-density polyethylene
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Hypothermic low-flow bypass (75 ml/kg per minute)
Trial: 8215281
Drug: Ciprofloxacin (250
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ciprofloxacin (250 mg orally)
Trial: 8215281
Drug: Ceftriaxone (250
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ceftriaxone (250 mg intramuscularly)
Trial: 2894217
Drug: ICI 118551
FDA approved: no
EMA approved: no
PMDA approved: no
Description: ICI 118551 (150 mg daily for 7 days)
Trial: 2894217
Drug: Propranolol (120
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Propranolol (120 mg daily for 7 days)
Trial: 20584877
Drug: Etoricoxib 120
RxNorm normalized name: etoricoxib 120 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Etoricoxib 120 mg x 1 x IV + 90 mg x 1 x day V-VII
Trial: 20584877
Drug: Tramadol sustained-release
RxNorm normalized name: tramadol Extended Release Oral Capsule
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tramadol sustained-release 100 mg x 2 x VII
Trial: 10394873
Drug: 2400 mg
RxNorm normalized name: pancreatin 2400 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 2400 mg of ferric ammonium citrate
Trial: 9116394
Drug: Oral pamidronate
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral pamidronate (300 mg/day for 4 weeks every 4 months)
Trial: 9116394
Drug: Oral pamidronate
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral pamidronate (150 mg/day for 4 weeks every 2 months)
Trial: 6657002
Drug: Nomifensine (200
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nomifensine (200 mg orally)
Trial: 28125735
Drug: Real-time fMRI
RxNorm normalized name: ethanol
DrugBank: Ethanol (DB00898)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Real-time fMRI neurofeedback training (4 weekly sessions, 60-min each)
Trial: 23429593
Drug: 6 mg/kg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 6 mg/kg aflibercept, 1-hour intravenous
Trial: 14505296
Drug: Sertraline (50
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sertraline (50 to 200 mg/d)
Trial: 14505296
Drug: Sertraline (147
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sertraline (147 mg)
Trial: 10381787
Drug: 7.5 mg/day
RxNorm normalized name: nicotine 7.5 MG/Day 24 HR Transdermal Patch
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 7.5 mg/day meloxicam
Trial: 6296755
Drug: Individual vaccines
RxNorm normalized name: Pertussis vaccine
DrugBank: Pertussis vaccine (DB15274)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Individual vaccines
Trial: 28375032
Drug: Test formulation
RxNorm normalized name: mumps skin test antigen
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Test formulation of dalteparin sodium (DS)
Trial: 28375032
Drug: Reference formulation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Reference formulation of dalteparin sodium (DS)
Trial: 11592727
Drug: Conjugated linoleic
RxNorm normalized name: CONJUGATED LINOLEIC ACID
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Conjugated linoleic acid (CLA) supplementation (4.2 g/d)
Trial: 11897986
Drug: Budesonide (400
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Budesonide (400 microg intranasally once daily)
Trial: 11897986
Drug: Cetirizine (10
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cetirizine (10 mg orally once daily)
Trial: 7573647
Drug: Open kinetic
RxNorm normalized name: Kineticream
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Open kinetic chain exercises using conventional physical therapy equipment
Trial: 2110972
Drug: IFN-gamma (0.03
FDA approved: no
EMA approved: no
PMDA approved: no
Description: IFN-gamma (0.03 mg/m2, 0.3 mg/m2, 1 mg/m2, 3 mg/m2)
Trial: 506644
Drug: 8 grams
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 8 grams of lecithin administered orally
Trial: 506644
Drug: 2 grams
RxNorm normalized name: phenylbutyrate
DrugBank: Phenylbutyric acid (DB06819)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 2 grams of placebo administered orally
Trial: 30653242
Drug: Aprepitant 80
RxNorm normalized name: aprepitant 80 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Aprepitant 80 mg/day for 4 weeks
Trial: 19658274
Drug: Magnesium sulfate
RxNorm normalized name: Magnesium Sulfate
DrugBank: Magnesium (DB14513)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Magnesium sulfate infusion for 10-14 days
Trial: 19658274
Drug: Control group
RxNorm normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control group (no magnesium sulfate infusion)
Trial: 16675938
Drug: Cisatracurium (0.15
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cisatracurium (0.15 mg/kg initial dose, 0.03 mg/kg maintenance)
Trial: 16675938
Drug: Vecuronium (0.1
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Vecuronium (0.1 mg/kg initial dose, 0.02 mg/kg maintenance)
Trial: 12145008
Drug: High-isoflavone soyfood
RxNorm normalized name: high-density polyethylene
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High-isoflavone soyfood diet (50 g soy protein and 73 mg isoflavones daily)
Trial: 12145008
Drug: Low-isoflavone soyfood
RxNorm normalized name: low-density polyethylene
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Low-isoflavone soyfood diet (52 g soy protein and 10 mg isoflavones daily)
Trial: 26867046
Drug: Standard care
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard care consisting of chemotherapy followed by endocrine therapy.
Trial: 26867046
Drug: Oncotype DX
RxNorm normalized name: brompheniramine maleate / dextromethorphan hydrobromide / pseudoephedrine hydrochloride Oral Solution [Myphetane DX]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oncotype DX test used to assign patients to treatment.
Trial: 26867046
Drug: Standard care
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard care if 'recurrence score' (RS) was > 25 or endocrine therapy alone if RS was ≤ 25.
Trial: 20054285
Drug: Nonbismuth quadruple
RxNorm normalized name: HUMAN PULMONARY SURFACTANT-ASSOCIATED PROTEIN D (PSPD, SURFACTANT PROTEIN D, SP-D, COLLECTIN-7, SURFACTANT PROTEIN D), NON-COVALENT QUADRUPLE TRIMER, PRODUCED IN HUMAN MYELOGENOUS LEUKEMIA K562 CELLS, GLYCOFORME ALFA
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nonbismuth quadruple therapy
Trial: 16382603
Drug: 3D displays
RxNorm normalized name: ethanol
DrugBank: Ethanol (DB00898)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 3D displays with appropriate cues (e.g., shadows)
Trial: 10218722
Drug: Propranolol, 160
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Propranolol, 160 mg/day (n = 37)
Trial: 10218722
Drug: Atenolol, 100
RxNorm normalized name: Atenolol, 100 mg oral tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Atenolol, 100 mg/day (n = 38)
Trial: 10218722
Drug: Bisoprolol, 10
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Bisoprolol, 10 mg/day (n = 39)
Trial: 10218722
Drug: Celiprolol, 400
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Celiprolol, 400 mg/day (n = 38)
Trial: 2213773
Drug: Clotrimazole (20
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Clotrimazole (20 mg/kg/day) 2 days a week for 12 weeks
Trial: 31347385
Drug: Cediranib alongside
RxNorm normalized name: cediranib
DrugBank: Cediranib (DB04849)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cediranib alongside chemotherapy followed by placebo maintenance (arm B)
Trial: 31347385
Drug: Placebo during
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo during chemotherapy and maintenance (arm A)
Trial: 29273007
Drug: nab-paclitaxel 125
RxNorm normalized name: Paclitaxel
DrugBank: Paclitaxel (DB01229)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: nab-paclitaxel 125 mg/m2 plus gemcitabine 1000 mg/m2 on days 1, 8, and 15 every 4 weeks
Trial: 26673577
Drug: nab-paclitaxel 125
RxNorm normalized name: Paclitaxel
DrugBank: Paclitaxel (DB01229)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: nab-paclitaxel 125 mg/m2 plus gemcitabine 1000 mg/m2
Trial: 17868430
Drug: Apixaban 5
RxNorm normalized name: apixaban 5 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Apixaban 5 mg q.d.
Trial: 17868430
Drug: Apixaban 10
RxNorm normalized name: Apixaban
DrugBank: Apixaban (DB06605)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Apixaban 10 mg b.i.d.
Trial: 17868430
Drug: Apixaban 20
RxNorm normalized name: Apixaban
DrugBank: Apixaban (DB06605)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Apixaban 20 mg b.i.d.
Trial: 17868430
Drug: Warfarin (titrated
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Warfarin (titrated to INR 1.8-3.0)
Trial: 17868430
Drug: Apixaban (all
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Apixaban (all doses)
Trial: 15135472
Drug: Sentinel node
RxNorm normalized name: Sentinel Spectrum
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sentinel node biopsy (SNB) using a peritumoural injection technique with blue dye and radiolabelled colloid mapping
Trial: 15135472
Drug: Standard axillary
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard axillary treatment after SNB
Trial: 12503706
Drug: Fluticasone propionate
RxNorm normalized name: Fluticasone Propionate
DrugBank: Fluticasone propionate (DB00588)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Fluticasone propionate (FP) 250 microg, twice daily for 12 weeks
Trial: 26333499
Drug: Dexmedetomidine (1
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dexmedetomidine (1 g/(kg.h) for 10 min, then 0.3 g/(kg.h) for 20 min)
Trial: 26333499
Drug: Midazolam (0.5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Midazolam (0.5 mg/kg for 60 s, then 0.04 mg/(kg.h) for 20 min)
Trial: 22940561
Drug: BZDs concurrent
FDA approved: no
EMA approved: no
PMDA approved: no
Description: BZDs concurrent with opioids
Trial: 22940561
Drug: Combination of
RxNorm normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination of BZDs and opioids
Trial: 11297596
Drug: Calcium (1200
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Calcium (1200 mg) plus Vitamin D(3) (800 IU)
Trial: 31606265
Drug: Anti-IL-17A treatment
RxNorm normalized name: Anti-IL-20
DrugBank: Fletikumab (DB12356)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Anti-IL-17A treatment
Trial: 24907778
Drug: Receiving multiple
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Receiving multiple HIV prevention messages (about PrEP, nPEP, rectal microbicides, and condoms)
Trial: 18720689
Drug: Doxycycline 100
RxNorm normalized name: doxycycline 100 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Doxycycline 100 mg daily plus oral levamisole 2.5 mg/kg/wk (up to 150 mg/wk)
Trial: 12462431
Drug: Amoxycillin/clavulanic acid
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Amoxycillin/clavulanic acid (AMX/CA) 875/125 mg b.i.d. for 14 days
Trial: 12462431
Drug: Cefuroxime axetil
RxNorm normalized name: Cefuroxime Axetil
DrugBank: Cefuroxime (DB01112)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Cefuroxime axetil 500 mg b.i.d. for 14 days
Trial: 7729023
Drug: Shock or
RxNorm normalized name: Medicated Pad or Tape
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Shock or antitachycardia pacing therapy
Trial: 1781288
Drug: Huperzine A
RxNorm normalized name: Huperzine A
DrugBank: Huperzine A (DB04864)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Huperzine A (0.05 mg bid for 4 weeks for multi-infarct dementia; 0.03 mg bid for 2 weeks for senile and presenile simple memory disorders)
Trial: 6452948
Drug: two‐ and
FDA approved: no
EMA approved: no
PMDA approved: no
Description: two‐ and three‐drug combinations
Trial: 6452948
Drug: three treatment
RxNorm normalized name: three-lobe sage extract
FDA approved: no
EMA approved: no
PMDA approved: no
Description: three treatment regimens
Trial: 31651370
Drug: Etelcalcetide (ETL)
DrugBank: Etelcalcetide (DB12865)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Etelcalcetide (ETL) administered intravenously after every hemodialysis session for 12 months
Trial: 31651370
Drug: Alfacalcidol administered
RxNorm normalized name: alfacalcidol
DrugBank: Alfacalcidol (DB01436)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Alfacalcidol administered intravenously after every hemodialysis session for 12 months
Trial: 27678271
Drug: Intraperitoneal bupivacaine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intraperitoneal bupivacaine (20 mL of 0.5% bupivacaine)
Trial: 27678271
Drug: Normal saline
RxNorm normalized name: Normal Saline Flush
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Normal saline (20 mL of 0.9% normal saline)
Trial: 25251885
Drug: Optimized Oral
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Optimized Oral Methadone (OOM)
Trial: 24052362
Drug: Metoprolol (5-10
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Metoprolol (5-10 mg)
Trial: 23044558
Drug: Topical mometasone
RxNorm normalized name: mometasone Topical Cream
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Topical mometasone ointment used twice a day for the first month and then once a day for 6 months on a few grafted lesions
Trial: 17420168
Drug: High-GDP PD
RxNorm normalized name: Poly Hist PD
DrugBank: Thonzylamine (DB11235)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High-GDP PD solution
Trial: 17420168
Drug: Low-GDP PD
RxNorm normalized name: Poly Hist PD
DrugBank: Thonzylamine (DB11235)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Low-GDP PD solution
Trial: 15689069
Drug: 2 mg/kg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 2 mg/kg body weight dihydroartemisinin (DHA)
Trial: 15689069
Drug: 4 mg/kg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 4 mg/kg body weight dihydroartemisinin (DHA)
Trial: 15689069
Drug: 4 mg/kg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 4 mg/kg body weight oral artesunate (AS)
Trial: 15689069
Drug: oral artesunate
RxNorm normalized name: Artesunate
DrugBank: Artesunate (DB09274)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: oral artesunate (AS)
Trial: 7535990
Drug: Red wine
RxNorm normalized name: Red wine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Red wine (400 ml per day, 11% alcohol)
Trial: 7535990
Drug: White wine
RxNorm normalized name: White wine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: White wine (400 ml per day, 11% alcohol)